Takeda Pharmaceutical to Release Sustained-Release Morphine Hydrochloride Capsule.
Tokyo, Japan, Apr 14, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) ) - Takeda Pharmaceutical has launched Passif, its proprietary sustained release Sustained-release (SR), extended-release (ER, XR, or XL), time-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin capsule of morphine hydrochloride morphine hydrochloride Warning - High-alert drug!
Dolora (CA), Morphitec (CA)
Pharmacologic class: Opioid agonist
Therapeutic class: Opioid analgesic
.
Available in three dosages 30mg, 60mg and 120mg, the new agent is indicated for the treatment of pain control for cancer patients with moderate to severe pain. It can exert beneficial effects with a once-a-day dosage.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion